好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The effect of race on accuracy of coding with ICD-10 code G20
Movement Disorders
P3 - Poster Session 3 (5:30 PM-6:30 PM)
10-042

To assess the accuracy in clinical use of the International Classification of Disease-10 (ICD-10) code G20 in identifying patients with idiopathic Parkinson’s Disease (PD) among White and African American races.

The ICD-10 code G20 is used for hemiparkinsonism, idiopathic PD, paralysis agitans, parkinsonism or PD not otherwise specified, and primary parkinsonism. Prior studies have evaluated the validity of ICD codes in identifying PD and found a positive predictive value (PPV) ranging from 44-83%. No studies have evaluated the effect of race on correctly identifying PD with the ICD-10 code G20.

A retrospective chart review was performed on all patients seen at the University of Alabama at Birmingham between 1/1/16 and 1/1/18 with the ICD-10 diagnosis code of G20.  A random sample of 50 patients that self-identified as White race and 50 patients that self-identified as African American race was used for analysis. Categorical variables were compared using a chi-squared test. Data was analyzed using SPS version 25.0 (IBM Corp., Armonk, NY). Statistical significance was defined as p<0.05.

The diagnosis code G20 correctly identified idiopathic PD patients more frequently in White versus African American patients (70% vs 46%, respectively, p=0.026). Atypical parkinsonism, essential tremor, an unclear diagnosis, and other diagnoses were found at similar frequencies within the White and African American groups. African American patients were more likely to have no documentation of a PD diagnosis in the chart (20% vs 4%) or to have drug-induced parkinsonism (8% vs 0%) than White patients (p=0.038).

In this retrospective chart review, G20 had a significantly lower PPV for accurately identifying idiopathic PD in African Americans than in Whites. A significant number of the African Americans coded as G20 did not have documentation of a PD diagnosis in the chart, and the reason for this discrepancy warrants further investigation.

Authors/Disclosures
Margi B. Patel, MD (Baylor Scott and White)
PRESENTER
No disclosure on file
No disclosure on file
David G. Standaert, MD, PhD, FAAN (Univ of Alabama - Dept of Neurology) Dr. Standaert has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie, Inc. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Curium. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Standaert has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CVS/Pharmacy. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HanAll Biopharma. Dr. Standaert has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Consultant for F. Hoffman LaRoche. Dr. Standaert has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Aventis. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance, Inc. Dr. Standaert has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for International Parkinson and Movement Disorder Society. The institution of Dr. Standaert has received research support from Abbvie, Inc. The institution of Dr. Standaert has received research support from American Parkinson Disease Association. The institution of Dr. Standaert has received research support from National Institutes of Health. The institution of Dr. Standaert has received research support from F. Hoffman LaRoche. Dr. Standaert has received publishing royalties from a publication relating to health care. Dr. Standaert has received personal compensation in the range of $500-$4,999 for serving as a Reviewer with National Institutes of Health. Dr. Standaert has a non-compensated relationship as a Chair, Scientific Advisory Board with American Parkinson Disease Association that is relevant to AAN interests or activities.
Marissa N. Dean, MD (The University of Alabama at Birmingham) The institution of Dr. Dean has received research support from Hoffman-La Roche. The institution of Dr. Dean has received research support from Vaccinex Inc.. The institution of Dr. Dean has received research support from Abbvie, Inc.. The institution of Dr. Dean has received research support from Retrophin, Inc.. The institution of Dr. Dean has received research support from Annexon, Inc.. The institution of Dr. Dean has received research support from Neurocrine Biosciences. The institution of Dr. Dean has received research support from Michael J. Fox Foundation for Parkinson's Research. The institution of Dr. Dean has received research support from CHDI Foundation. The institution of Dr. Dean has received research support from Eli Lily and Company. The institution of Dr. Dean has received research support from United States Army Medical Research and Development Command. The institution of Dr. Dean has received research support from UniQure Biopharma B.V.. The institution of Dr. Dean has received research support from Neuraly, Inc.. The institution of Dr. Dean has received research support from Praxis Precision Medicines.